A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 Interferonopathies

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 29, 2025

Primary Completion Date

December 6, 2026

Study Completion Date

December 7, 2026

Conditions
Type 1 Interferonopathies
Interventions
DRUG

BI 3000202_low dose

BI 3000202\_low dose

DRUG

BI 3000202_high dose

BI 3000202\_high dose

Trial Locations (18)

9000

NOT_YET_RECRUITING

UNIV UZ Gent, Ghent

19104

NOT_YET_RECRUITING

Children's Hospital of Philadelphia, Philadelphia

25123

NOT_YET_RECRUITING

ASST degli Spedali Civili di Brescia, Brescia

28046

RECRUITING

Hospital La Paz, Madrid

34124

NOT_YET_RECRUITING

Azienda Sanitaria Universitaria Giuliano Isontina, Trieste

34295

NOT_YET_RECRUITING

HOP Gui de Chauliac, Montpellier

41013

NOT_YET_RECRUITING

Hospital Virgen del Rocío, Seville

72076

NOT_YET_RECRUITING

Universitätsklinikum Tübingen, Tübingen

75015

NOT_YET_RECRUITING

HOP Necker, Paris

75020

NOT_YET_RECRUITING

HOP Tenon, Paris

77030

NOT_YET_RECRUITING

Texas Children's Hospital, Houston

90027

NOT_YET_RECRUITING

Children's Hospital Los Angeles, Los Angeles

94121

NOT_YET_RECRUITING

University of California San Francisco, San Francisco

7830604

NOT_YET_RECRUITING

Barzilai Medical Center, Ashkelon

01307

RECRUITING

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

1649-035

NOT_YET_RECRUITING

ULS de Santa Maria, E.P.E, Lisbon

4099-001

NOT_YET_RECRUITING

ULS de Santo Antônio, E.P.E - Centro Hospitalar Universitário de Santo António, Porto

08035

NOT_YET_RECRUITING

Hospital Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY